Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mixed-lineage leukemia (MLL) gene rearranged Acute Lymphoblastic Leukemia (ALL), that does not respond to treatment or has relapsed from prior treatment; or FLT3 mutated Acute Myeloid Leukemia (AML) that does not respond to a second treatment or has relapsed from 2 prior treatments~* Normal organ function, and chest x-ray~* Expected survival greater than 8 weeks~* Can care for most of personal needs and perform at least minimum activity~Exclusion Criteria:~* Patients with symptomatic leukemic central nervous system involvement or isolated extramedullary leukemia~* Patients must not have received other treatments for leukemia within a predefined time period, 72 hours for medications, 2 months for transplants~* Patients with heart function that is not normal~* Patients with HIV or hepatitis~* Patients with another severe disease or medical condition besides leukemia Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 30 mg/m^2 bid (Type: EXPERIMENTAL): Participants received bodyweight and body surface area (BSA) stratified dose of midostaurin 30 mg/m\^2 twice daily (bid) through oral route. The total daily dose in 30 mg/m\^2 bid cohort was 60 mg/m\^2.
- 60 mg/m^2 bid (Type: EXPERIMENTAL): Participants received bodyweight and BSA stratified dose of midostaurin 60 mg/m\^2 bid through oral route. The total daily dose in 60 mg/m\^2 bid cohort was 120 mg/m\^2.

Based on this trial design, predict the completion outcome and termination type (if applicable).